Investors’ Patience Is Being Tested Right Now By ImmunityBio Inc (NASDAQ: IBRX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

ImmunityBio Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $4.31 and fluctuated between $4.3200 as its day high and $4.0200 as its day low. The current market capitalization of ImmunityBio Inc is $2.88B. A total of 2.45 million shares were traded on the day, compared to an average of 4.19M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, IBRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 14 BUYs and 0 SELLs from insiders. Insiders purchased 209,577,696 shares during that period but sold 0.

In the most recent transaction, BLASZYK MICHAEL D bought 71,915 shares of IBRX for 2.75 per share on Jun 05. After the transaction, the Director now owns 71,915 company shares. In a previous transaction on Jun 02, Brennan John Owen bought 25,000 shares at 2.83 per share. IBRX shares that Director owns now total 25,000.

Among the insiders who bought shares, Clark Wesley acquired of 7,000 shares on Jun 01 at a per-share price of $2.91. This resulted in the Director holding 8,000 shares of IBRX after the transaction.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for IBRX in the last 3 months, the mean price target is $4.00 with high estimates of $4.00 and low estimates of $4.00. In terms of 52-week highs and lows, IBRX has a high of $6.93 and a low of $1.21.

As of this writing, IBRX has an earnings estimate of -$0.18 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.18 per share and a lower estimate of -$0.18. The company reported an EPS of -$0.32 in the last quarter, which was -39.10% lower than expectations of -$0.23.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. IBRX’s latest balance sheet shows that the firm has $317.12M in Cash & Short Term Investments as of fiscal 2021. There were $645.66M in debt and $369.00M in liabilities at the time. Its Book Value Per Share was -$0.62, while its Total Shareholder’s Equity was -$243.91M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IBRX is Buy with a score of 4.00.

Most Popular

Related Posts